SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 139 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,389,250 | -5.5% | 440,031 | +36.2% | 0.55% | -16.5% |
| Q2 2023 | $6,763,195 | -67.2% | 323,134 | -66.9% | 0.65% | -58.6% |
| Q1 2023 | $20,606,890 | -17.0% | 975,705 | 0.0% | 1.58% | -1.9% |
| Q4 2022 | $24,831,692 | -26.5% | 975,705 | -30.6% | 1.61% | -26.4% |
| Q3 2022 | $33,773,000 | -34.1% | 1,405,428 | -47.2% | 2.19% | -14.9% |
| Q2 2022 | $51,238,000 | +9.5% | 2,663,087 | -1.1% | 2.57% | +24.1% |
| Q1 2022 | $46,792,000 | -29.9% | 2,692,303 | -11.7% | 2.07% | -11.9% |
| Q4 2021 | $66,777,000 | +31.5% | 3,050,559 | +14.8% | 2.35% | +46.8% |
| Q3 2021 | $50,778,000 | +14.0% | 2,657,159 | +2.5% | 1.60% | +26.5% |
| Q2 2021 | $44,528,000 | -0.5% | 2,593,337 | +29.5% | 1.26% | -3.4% |
| Q1 2021 | $44,774,000 | +11.9% | 2,002,410 | +11.3% | 1.31% | +5.6% |
| Q4 2020 | $39,998,000 | +102.4% | 1,798,453 | +34.3% | 1.24% | +105.1% |
| Q3 2020 | $19,759,000 | – | 1,338,691 | – | 0.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |